<DOC>
	<DOC>NCT02633007</DOC>
	<brief_summary>This study is a double-blind, randomized, placebo-controlled, 2-period, crossover study to evaluate safety and PK of 3 doses of CVT 301 levodopa (l-dopa) in adults with asthma.</brief_summary>
	<brief_title>A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Eligible subjects will be men or women in good general health with a diagnosis of mild or moderate asthma; On a stable regimen of asthma medications for at least 30 days prior to screening; Body mass index (BMI) 18 to 32 kg/m2; Forced expiratory volume in one second (FEV1) ≥60% of predicted for race, age, sex, and height; FEV1/FVC (forced vital capacity) ratio ≥70%. More than 2 hospitalizations or emergency room visits, or more than 3 courses of systemic steroids in the past 12 months or 1 course within the past 8 weeks for respiratory illness; Asthma exacerbation within 8 weeks before screening; Unscheduled or urgent visit to any medical facility for asthmarelated problems within 8 weeks before screening; History of intubation or intensive care unit admission for asthma in the past 5 years; History of chronic obstructive pulmonary disorder (COPD) requiring intermittent or continuous use of any oral or inhaled medication therapy within last 3 years; Renal impairment as defined by a calculated creatinine clearance of ≤ 80 mL/minute.</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>